Skip to main content
ONCIMMUNE HOLDINGS PLC logo

ONCIMMUNE HOLDINGS PLC — Investor Relations & Filings

Ticker · ONC ISIN · GB00BYQ94H38 LEI · 213800HCYIWT6YPI1I02 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2020-10-21 Regulatory Filings
Country GB United Kingdom
Listing IL ONC

About ONCIMMUNE HOLDINGS PLC

https://www.oncimmune.com/

Oncimmune Holdings PLC is a precision medicine and immunodiagnostics company specializing in the discovery and application of antibody and autoantibody biomarker signatures. The company's core technology is the ImmunoINSIGHTS™ platform, an advanced analytical engine for immune profiling. This platform utilizes a proprietary library of over 9,000 human antigens, bead-based multiplexed immunoassay technology, and machine learning algorithms to generate biological insights from minimal sample volumes. Oncimmune applies its expertise across therapeutic areas including immuno-oncology, autoimmune diseases, and infectious diseases. It provides biomarker discovery services, targeted panels, and advanced bioinformatics to support pharmaceutical and biotechnology partners in developing more effective and targeted treatments and diagnostics.

Recent filings

Filing Released Lang Actions
Abstracts of Studies using EarlyCDT Lung
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7105C' and is dated '21 October 2020'. It details company news regarding abstracts of studies being presented at a medical conference (CHEST Annual Meeting 2020) concerning their EarlyCDT Lung blood test. The footer explicitly states, 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This structure—a brief announcement disseminated via the RNS system about company developments that are not formal financial reports (like 10-K, IR, or ER)—points towards a general regulatory announcement or press release. Since it is a formal announcement distributed through the RNS system but doesn't fit the specific categories like DIV, MANG, or ER, the most appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (7923 chars), but its content is purely informational news release distributed via the RNS platform.
2020-10-21 English
Replacement: Notice of Full Year Results
Report Publication Announcement Classification · 99% confidence The document is an official announcement released via RNS (RNS Number: 4610C) from Oncimmune Holdings PLC. The primary purpose of the text is to issue a 'Replacement Notice of Full Year Results ended 31 May 2020' and provide details about the upcoming results presentation, conference call, and investor meet-up schedule. It is not the full results document (10-K or IR) itself, nor is it a transcript (CT) or a general presentation (IP). Since it is an announcement regarding the publication of results and related events, and it is distributed through the RNS system, it fits best under the category of a general regulatory announcement or a notice about a report publication. Given the specific content is announcing the timing and logistics for the release of full-year results, 'Report Publication Announcement' (RPA) is highly appropriate, as it is announcing *when* and *how* the results will be shared. However, since it is a formal regulatory news service release (RNS) that details an upcoming event related to financial reporting, 'RNS' (Regulatory Filings) is also a strong candidate, but RPA is more specific to the action described (announcing the publication/presentation of results). Given the structure and the explicit mention of correcting the link for the presentation, RPA is the most precise fit for this type of logistical announcement preceding the main filing.
2020-10-19 English
Notice of Full Year Results ended 31 May 2020
Report Publication Announcement Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 4022C' and the footer referencing RNS/LSE) dated October 19, 2020. The core content is the 'Notice of Full Year Results ended 31 May 2020', stating that the full year results will be announced on Friday, 30 October 2020. This document is not the full results report itself (which would likely be a 10-K or IR), but rather an announcement about the *timing* and logistics (conference calls, investor presentation) of the upcoming results release. According to Rule 2, when a document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2020-10-19 English
Agreement with Cedars-Sinai to Profile COVID-19
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 8535B' and is dated '13 October 2020'. It announces a specific commercial agreement between Oncimmune Holdings plc and Cedars-Sinai regarding COVID-19 profiling. The text concludes with standard disclaimers and contact information related to RNS (Regulatory News Service) distribution. This format strongly indicates a general regulatory announcement disseminated via the London Stock Exchange's news service, which aligns best with the 'Regulatory Filings' category (RNS), as it is not a formal financial report (10-K, IR, ER) or a specific corporate action like a dividend or management change.
2020-10-13 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document text is very short (1907 characters) and contains the header 'RNS Number : 5283B' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific type of market announcement. This type of immediate, brief regulatory update that doesn't fit into the specific financial reporting categories (like 10-K, ER, IR) is best classified under the general regulatory announcement category, RNS.
2020-10-08 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1890 characters) and contains clear identifiers like 'RNS Number : 5270B' and mentions 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific operational update related to trading mechanisms rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a direct, short regulatory announcement distributed via the RNS system, and it doesn't fit into the more specific categories like DIRS, DIV, or ER, the most appropriate classification is the general regulatory filing/announcement category.
2020-10-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.